Dolby Laboratories (NYSE:DLB) Downgraded by Wall Street Zen to Hold

Dolby Laboratories (NYSE:DLB) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Other equities research analysts also recently issued research reports about the company. Rosenblatt Securities cut their price objective on Dolby Laboratories from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, November 19th. Robert W. Baird assumed coverage on Dolby Laboratories in a report on Friday, September 5th. They set a “neutral” rating and a $74.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a research report on Monday, December 22nd. Barrington Research cut their price objective on Dolby Laboratories from $100.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, November 19th. Finally, Baird R W upgraded shares of Dolby Laboratories to a “hold” rating in a report on Friday, September 5th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Dolby Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.00.

Dolby Laboratories Price Performance

Shares of DLB opened at $65.69 on Friday. The firm’s 50 day moving average is $66.51 and its 200-day moving average is $70.81. Dolby Laboratories has a 12-month low of $64.02 and a 12-month high of $89.66. The stock has a market capitalization of $6.27 billion, a P/E ratio of 24.98 and a beta of 0.89.

Dolby Laboratories (NYSE:DLB) last released its earnings results on Tuesday, November 18th. The electronics maker reported $0.99 EPS for the quarter, beating the consensus estimate of $0.70 by $0.29. The business had revenue of $307.02 million during the quarter, compared to analyst estimates of $305.76 million. Dolby Laboratories had a net margin of 18.90% and a return on equity of 11.99%. The business’s quarterly revenue was up .7% on a year-over-year basis. During the same period in the prior year, the business earned $0.61 earnings per share. Dolby Laboratories has set its FY 2026 guidance at 4.190-4.340 EPS and its Q1 2026 guidance at 0.790-0.940 EPS. As a group, equities research analysts forecast that Dolby Laboratories will post 2.94 EPS for the current fiscal year.

Insider Activity at Dolby Laboratories

In other news, EVP Mark Andrew Sherman sold 9,109 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $66.73, for a total value of $607,843.57. Following the transaction, the executive vice president directly owned 73,054 shares of the company’s stock, valued at approximately $4,874,893.42. This represents a 11.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Shriram Revankar sold 3,000 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $65.55, for a total value of $196,650.00. Following the sale, the senior vice president owned 67,435 shares of the company’s stock, valued at approximately $4,420,364.25. This represents a 4.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 162,120 shares of company stock worth $10,906,559 in the last 90 days. 37.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dolby Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the company. American Century Companies Inc. increased its position in Dolby Laboratories by 93.9% in the 1st quarter. American Century Companies Inc. now owns 41,860 shares of the electronics maker’s stock worth $3,362,000 after buying an additional 20,272 shares during the period. MetLife Investment Management LLC grew its stake in shares of Dolby Laboratories by 1.0% in the first quarter. MetLife Investment Management LLC now owns 33,967 shares of the electronics maker’s stock worth $2,728,000 after acquiring an additional 349 shares during the last quarter. Ieq Capital LLC bought a new position in Dolby Laboratories during the first quarter worth $2,278,000. OMERS ADMINISTRATION Corp bought a new position in Dolby Laboratories during the first quarter worth $932,000. Finally, Magnetar Financial LLC raised its stake in Dolby Laboratories by 456.9% during the 1st quarter. Magnetar Financial LLC now owns 20,682 shares of the electronics maker’s stock valued at $1,661,000 after purchasing an additional 16,968 shares during the last quarter. 58.56% of the stock is owned by hedge funds and other institutional investors.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.

Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.